Effectiveness of Cladribine Tablets in Participants With Highly-active Relapsing Multiple Sclerosis (CAMELOT-MS)

Cladribine Tablets in Highly-active Relapsing Multiple Sclerosis - Real-World Effectiveness in UK Clinical Practice (CAMELOT-MS)

The main purpose of this study was to investigate the effectiveness of cladribine tablets in a UK real-world setting.

Inclusion Criteria:

• Physician diagnosis of HDA-RRMS as defined by clinical or radiological features
• Treatment initiation with cladribine tablet monotherapy on or after 22 August 2017 and at least 3 years before enrolment
• Completion of Year 1 treatment of cladribine tablets (Week 1 and Week 2 treatment, per recommended dose in Year 1: 1.75 milligrams per kilogram [mg/kg] body weight, cumulatively)

Exclusion Criteria:

• Received cladribine tablet treatment within an interventional clinical trial during the study period
• Received treatment with any investigational therapy for RRMS in the 6 months prior to cladribine tablet treatment initiation